LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

LLY

1,007.49

+1.43%↑

JNJ

194.4

+1%↑

ABBV

231.07

+3.48%↑

UNH

340.72

+5.63%↑

AZN

88.56

-0.25%↓

Search

Repligen Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

156.02 1.85

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

151.11

Max

156.41

Pagrindiniai rodikliai

By Trading Economics

Pajamos

9M

15M

Pardavimai

6.4M

189M

P/E

Sektoriaus vid.

7,508.5

77.256

Pelnas, tenkantis vienai akcijai

0.46

Pelno marža

8.152

Darbuotojai

1,778

EBITDA

-98M

-54M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+25.88% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-909M

8.4B

Ankstesnė atidarymo kaina

154.17

Ankstesnė uždarymo kaina

156.02

Naujienos nuotaikos

By Acuity

17%

83%

28 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Repligen Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-11 23:59; UTC

Uždarbis

Singtel's 1st Half Net Profit Surges

2025-11-11 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

2025-11-11 22:21; UTC

Uždarbis

Aristocrat Boosts Dividend as Annual Profit Rises 12%

2025-11-11 23:52; UTC

Rinkos pokalbiai

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

2025-11-11 23:44; UTC

Uždarbis

Singtel's 1H Net Profit Surges

2025-11-11 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

2025-11-11 23:18; UTC

Uždarbis

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

2025-11-11 23:15; UTC

Uždarbis

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

2025-11-11 23:14; UTC

Uždarbis

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

2025-11-11 23:12; UTC

Uždarbis

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

2025-11-11 23:11; UTC

Uždarbis

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

2025-11-11 23:10; UTC

Uždarbis

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

2025-11-11 23:04; UTC

Rinkos pokalbiai

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

2025-11-11 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-11 21:50; UTC

Rinkos pokalbiai
Uždarbis

Health Care Roundup: Market Talk

2025-11-11 21:46; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

2025-11-11 21:41; UTC

Uždarbis

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

2025-11-11 21:40; UTC

Uždarbis

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

2025-11-11 21:39; UTC

Uždarbis

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

2025-11-11 21:39; UTC

Uždarbis

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

2025-11-11 21:39; UTC

Uždarbis

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

2025-11-11 21:38; UTC

Uždarbis

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

2025-11-11 21:38; UTC

Uždarbis

Aristocrat: Final Dividend 49 Australian Cents/Share

2025-11-11 21:37; UTC

Uždarbis

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

2025-11-11 21:36; UTC

Uždarbis

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

2025-11-11 21:35; UTC

Uždarbis

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

2025-11-11 21:35; UTC

Uždarbis

Alcon 3Q Adj EPS 79c >ALC

2025-11-11 21:35; UTC

Uždarbis

Alcon 3Q Rev $2.61B >ALC.EB

2025-11-11 21:35; UTC

Uždarbis

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

2025-11-11 21:35; UTC

Uždarbis

Alcon 3Q EPS 48c >ALC.EB

Akcijų palyginimas

Kainos pokytis

Repligen Corp Prognozė

Kainos tikslas

By TipRanks

25.88% į viršų

12 mėnesių prognozė

Vidutinis 183.36 USD  25.88%

Aukščiausias 220 USD

Žemiausias 135 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Repligen Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

15 ratings

11

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

125.31 / 140.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

28 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat